CTI BioPharma (CTIC) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Noncontrolling interest: 178K
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Noncontrolling interest: 178K
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
CTI BioPharma (NASDAQ: CTIC) reported Q1 EPS of ($0.71), $0.01 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $8 thousand, versus $36.5 million reported last year.
For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Upstart Holdings (UPST) Tops Q3 EPS by 12c ; Offers Guidance
- AdaptHealth Corp. (AHCO) Misses Q3 EPS by 120c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
